HAGENS BERMAN Encourages Athira Pharma (ATHA) Investors to Contact Firm's Attorneys Now, SECURITIES FRAUD LAWSUIT FILED, Application Deadline Approaching
HAGENS BERMAN Encourages Athira Pharma (ATHA) Investors to Contact Firm's Attorneys Now, SECURITIES FRAUD LAWSUIT FILED, Application Deadline Approaching
SAN FRANCISCO, CA / ACCESSWIRE / July 9, 2021 / Hagens Berman urges Athira Pharma, Inc. (NASDAQ:ATHA) investors with significant losses tosubmit your losses now. A securities class action has been filed and certain investors may have valuable claims.
加利福尼亞州舊金山/ACCESSWIRE/2021年7月9日/Hagens Berman敦促Athera Pharma，Inc.。(納斯達克股票代碼：ATSA)蒙受重大損失的投資者現在提交你的損失。證券集體訴訟已經提起，某些投資者可能會提出有價值的索賠。
Class Period: Sept. 18, 2020 - June 17, 2021
上課時間：9月2020年6月18日-2021年6月17日
Lead Plaintiff Deadline: Aug. 24, 2021
首席原告截止日期：2021年8月24日
Visit:www.hbsslaw.com/investor-fraud/ATHA
訪問：www.hbsslaw.com/Investor-Fragence/Atha
Contact An Attorney Now:ATHA@hbsslaw.com
立即聯繫律師：atha@hbsslaw.com
844-916-0895
844-916-0895
Athira Pharma, Inc. (ATHA) Securities Class Action:
Athera Pharma，Inc.(ATSA)證券集體訴訟：
Since going public in September 2020, Athira and senior management have repeatedly emphasized the importance of CEO Leen Kawas' doctoral research to the company's product candidates intended to treat Alzheimer's.
自2020年9月上市以來，Athera和高級管理層一再強調首席執行官Leen Kawas的博士研究對公司旨在治療阿爾茨海默氏症的產品候選人的重要性。
According to the lawsuit, Defendants failed to disclose to investors that research conducted by Kawas, which formed the foundation for Athira's product candidates and intellectual property, was tainted by Kawas' scientific misconduct, including manipulation of key data.
根據起訴書，被告未能向投資者披露，卡瓦斯進行的研究受到卡瓦斯科學不當行為的影響，包括操縱關鍵數據。卡瓦斯的研究構成了AThia產品候選和知識產權的基礎。
Investors began to learn the truth, according to the complaint, after the market closed on June 17, 2021, when the company announced its board placed Kawas on temporary leave pending its review of Kawas' published research while at Washington State University. The same day, STAT News reported Athira's decision was based on allegations of altered images in four separate papers on which Kawas was the lead author. STAT reported Washington State University is also conducting a review and "[t]he allegedly altered images call into question the validity of entire studies, said several Alzheimer's experts."
根據起訴書，投資者在2021年6月17日股市收盤後開始瞭解真相，當時該公司宣佈董事會讓卡瓦暫時休假，等待對卡瓦在華盛頓州立大學(Washington State University)發表的研究進行審查。同一天，STAT新聞報道説，阿瑟拉的決定是基於四份單獨的報紙上關於圖片被篡改的指控，卡瓦斯是這四份報紙的主要作者。據Stat報道，華盛頓州立大學也在進行一項審查，“[t]幾位阿爾茨海默氏症專家表示，他涉嫌篡改圖像，令整個研究的有效性受到質疑。
In addition, Barron's reported Stifel analyst Paul Matteis said "[w]e really don't know how to process this development" and "[t]he scientific hypothesis behind Athira came out of the work [that] Dr. Kawas did in graduate school so there is risk here that whatever comes out of this investigation could have clear negative implications for how we/investors view the asset, and/or management credibility."
此外，Barron‘s報道的Stifel分析師保羅·馬泰斯(Paul Matteis)表示。[w]我們真的不知道如何處理這一事態發展“和”[t]阿瑟拉背後的科學假説是從這項工作中得出的。[那]卡瓦斯博士在研究生院時就是這樣做的，所以這裏存在這樣的風險，即無論調查結果如何，都可能對我們/投資者如何看待資產和/或管理信譽產生明顯的負面影響。“
This news sent the price of Athira shares crashing lower.
這一消息導致Athera股價暴跌。
"We're focused on investors' losses and proving defendants knew Kawas' doctoral research did not support the company's lead product candidate ATH-1017," said Reed Kathrein, the Hagens Berman partner leading the investigation.
領導此次調查的Hagens Berman合夥人裏德·卡特林(Reed Katriin)表示：“我們關注的是投資者的損失，並證明被告知道Kawas的博士研究不支持該公司的主要候選產品ATH-1017。”
If you are a Athira investor and have significant losses, or have knowledge that may assist the firm's investigation,click here to discuss your legal rights with Hagens Berman.
如果您是Athera的投資者，並且有重大損失，或者您知道可能有助於公司調查的信息，請單擊此處與Hagens Berman討論您的合法權利。
Whistleblowers: Persons with non-public information regarding Athira should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or emailATHA@hbsslaw.com.
舉報人：擁有關於Athera的非公開信息的人應該考慮他們的選擇，以幫助調查或利用SEC舉報人計劃。根據新計劃，提供原始信息的舉報人可能會獲得SEC任何成功追回的高達30%的獎勵。欲瞭解更多信息，請致電裏德·卡特林，電話：844-916-0895，或發電子郵件至ATHA@hbsslaw.com。
About Hagens Berman
關於哈根斯·伯曼
Hagens Berman is a national law firm with eight offices in eight cities around the country and over eighty attorneys. The firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes is located athbsslaw.com. For the latest news visit ournewsroomor follow us on Twitter at@classactionlaw.
Hagens Berman是一家全國性律師事務所，在全國8個城市設有8個辦事處，擁有80多名律師。該公司在複雜的訴訟中代表投資者、舉報人、工人和消費者。有關該公司及其成功的更多信息，請訪問athbsslaw.com。有關最新新聞，請訪問我們的新聞編輯室或在Twitter上關注我們@classactionlaw。
Contact:
聯繫方式：
Reed Kathrein, 844-916-0895
裏德·卡蘇林，電話：844-916-0895
SOURCE: Hagens Berman
消息來源：哈根斯·伯曼(Hagens Berman)
View source version on accesswire.com:https://www.accesswire.com/654947/HAGENS-BERMAN-Encourages-Athira-Pharma-ATHA-Investors-to-Contact-Firms-Attorneys-Now-SECURITIES-FRAUD-LAWSUIT-FILED-Application-Deadline-Approaching
查看accesswire.com:https://www.accesswire.com/654947/HAGENS-BERMAN-Encourages-Athira-Pharma-ATHA-Investors-to-Contact-Firms-Attorneys-Now-SECURITIES-FRAUD-LAWSUIT-FILED-Application-Deadline-Approaching上的源代碼版本
COMTEX_389573799/2457/2021-07-09T13:20:31
COMEX_389573799/2457/2021-07-09T13：20：31
譯文內容由第三人軟體翻譯。